Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
Company Announcement Net sales of DARZALEX® in 2025 totaled USD 14,351 millionGenmab receives royalties on worldwide net sales from Johnson...
Cancer
Comphya Announces Publication of CaverSTIM First-in-Man Clinical Study in BJUI and Scientific Review in Nature Urology
Peer-reviewed publications validate the scientific foundation and early clinical potential of CaverSTIM™ in restoring erectile functionLAUSANNE, Switzerland, Jan. 21, 2026...
IO Biotech Announces Exploration of Strategic Alternatives
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf...
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders
BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company with a...
Erasca Announces Proposed Public Offering of $150 Million of Common Stock
SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...
Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today...
BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS)
VANCOUVER, BC / ACCESS Newswire / January 21, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased...
Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics
Montreal, Quebec--(Newsfile Corp. - January 21, 2026) - Defence Therapeutics Inc., (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the...
Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics
Montreal, Quebec--(Newsfile Corp. - January 21, 2026) - Defence Therapeutics Inc., (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the...
HistoIndex Partners with Houston Research Institute to Expand Advanced MASH Diagnostic Services
SINGAPORE, Jan. 20, 2026 /PRNewswire/ -- HistoIndex, a pioneer in AI-driven digital pathology solutions for chronic liver disease, has announced...
Rakuten Medical Expands Academic Access to IR700 Dye Through Fee-Only Provision, Greater Publication Freedom and Expanded IP & Commercialization Opportunities
Rakuten Medical's light-activatable IR700 dye is a clinically validated component used in the approved medicine Akalux™With hydrophilicity and low toxicity1,...
Abcam joins the Innovative Health Initiative LIGAND-AI project to advance artificial intelligence (AI)-driven drug discovery through open science
Abcam has joined an industry-academic partnership led by the Structural Genomics Consortium and Pfizer to advance AI-driven drug discovery through...
Abcam joins the Innovative Health Initiative LIGAND-AI project to advance artificial intelligence (AI)-driven drug discovery through open science
Abcam has joined an industry-academic partnership led by the Structural Genomics Consortium and Pfizer to advance AI-driven drug discovery through...
Abcam joins the Innovative Health Initiative LIGAND-AI project to advance artificial intelligence (AI)-driven drug discovery through open science
Abcam has joined an industry-academic partnership led by the Structural Genomics Consortium and Pfizer to advance AI-driven drug discovery through...
HT Vet’s VISTA iQ™ Introduces New Cancer Diagnostic Service, Unlocking $130K in Annual Revenue for Veterinary Clinics
Clinics equipped with the scanner hold the key to early cancer detection for dogs, lowering costs for pet owners and...
HT Vet’s VISTA iQ™ Introduces New Cancer Diagnostic Service, Unlocking $130K in Annual Revenue for Veterinary Clinics
Clinics equipped with the scanner hold the key to early cancer detection for dogs, lowering costs for pet owners and...
HT Vet’s VISTA iQ™ Introduces New Cancer Diagnostic Service, Unlocking $130K in Annual Revenue for Veterinary Clinics
Clinics equipped with the scanner hold the key to early cancer detection for dogs, lowering costs for pet owners and...
Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis
The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan...
Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis
The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan...
Brainomix e-Lung AI Imaging Technology Selected as Co-Primary Endpoint in Boehringer Ingelheim Phase 3 Clinical Trial in Pulmonary Fibrosis
The DROP-FPF trial is the first Phase 3 trial in interstitial lung disease (ILD) to use automated, quantitative high-resolution CT scan...